Most Recent Articles by Stan Grossman
A survey showed 67.3% of patient advocacy organizations received industry funding, while 11.9% received more than half of their funding from industry.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Intrathecal dosing of neural progenitors appears to be safe and well tolerated in patients with progressive multiple sclerosis.
Investigational agent has the potential to repair damaged myelin sheath and restore function in patients with secondary-progressive multiple sclerosis.
Patients with MS were likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years.
More Articles by Stan Grossman
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd